Navigation Links
China Medicine Corporation Adopts New Incentive Compensation Plans

GUANGZHOU, China, March 3, 2011 /PRNewswire-Asia-FirstCall/ -- China Medicine Corporation (OTC Bulletin Board: CHME) (the "Company"), a leading manufacturer, developer and distributor of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other health products in the People's Republic of China, today announced that the Board of Directors (the "Board") adopted, subject to stockholder approval, the 2011 Long-Term Incentive Plan (the "2011 Incentive Plan"), covering a maximum of 4 million shares of common stock, par value $0.0001 per share, of the Company (the "Common Stock"). The plan provides for the grant of incentive and non-qualified stock options, stock appreciation rights, restricted shares and other equity-based incentives to employees, directors, and consultants.

The 2011 Incentive Plan is designed to further and promote the interests of the Company, its subsidiaries and its shareholders by enabling the Company and its subsidiaries to attract, retain and motivate existing and prospect employees, directors and consultants, and to align the interests of those individuals and the Company's shareholders.

The Board's Compensation Committee (the "Compensation Committee") will administer the 2011 Incentive Plan, review with management the adoption, amendment and termination of the 2011 Incentive Plan, and approve grants and awards under the 2011 Incentive Plan. In the absence of the Compensation Committee, the 2011 Incentive Plan will be administered by the Board. Each participant receiving an award under the 2011 Incentive Plan will enter into an award agreement (the "Award") with the Company in a form specified by the Compensation Committee. Each such participant shall agree to the restrictions, terms and conditions of the Award set forth therein and in the 2011 Incentive Plan.

Pursuant to the 2011 Incentive Plan, on February 25, 2011 the Company granted various employees of the Company non-qualified stock options to purchase an aggregate of 500,000 shares of Common Stock at $1.80 per share. The option grants are subject to stockholder approval of the 2011 Incentive Plan.

The company's new incentive plans are further described in an exhibit to the Form 8-K that the company filed today with the Securities and Exchange Commission.

About China Medicine CorporationChina Medicine Corporation, a vertically integrated enterprise with a research and development centre, manufacturing facility and well established sales network, engages in the production and distribution of prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company is developing a number of proprietary products for a variety of indications, including oncology, high blood pressure and toxin removal from food and animal feeds. For more information, please visit the Company's website at The Company routinely posts important information on its website.

Safe-Harbor Statement This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.Contact InformationICR, Inc.In New York: Ms. Christine Duan: 1-203-682-8200In Beijing: Ms. Wen Lei Zheng: 86-10-6599-7968

SOURCE China Medicine Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DK Sinopharma, Inc. is to Present at the Rodman & Renshaw Annual China Investment Conference to be Held March 6--8
2. China Pharma Holdings, Inc. Reports Full Year 2010 Financial Results
3. China Pharma Holdings, Inc. to Report Fiscal Year 2010 Financial Results on March 3, 2011
4. China Nepstar Chain Drugstore to Report Fourth Quarter and Fiscal Year 2010 Financial Results on March 16, 2011
5. Health on the Agenda at Food ingredients Asia-China Trade Show
6. Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China
7. NSF International Opens NSF Shanghai Testing Laboratory in China to Support Increasing Demand for Testing and Certification Services
8. Global Sources extends its contract with AsiaWorld-Expo to host China Sourcing Fairs in Hong Kong through 2014
9. Additional 8 Products of DK Sinopharma, Inc. are Included in 2010 Provincial Medical Insurance Catalogs in 4 Separate Provinces in the Peoples Republic of China
10. China Medical Technologies Reports Third Fiscal Quarter Financial Results
11. China SHESAYS Updates on Progress of Commencing Operations at its New Flagship Hospital
Post Your Comments:
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based ... and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored ... 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, ...
Breaking Medicine News(10 mins):